PD-1/PD-L1 and immunotherapy for pancreatic cancer

被引：258

作者：

Feng, Mengyu ^{[1
,2
]}

Xiong, Guangbing ^{[1
,2
,3
]}

Cao, Zhe ^{[1
,2
]}

Yang, Gang ^{[1
,2
]}

Zheng, Suli ^{[1
,2
]}

Song, Xujun ^{[1
,2
]}

You, Lei ^{[1
,2
]}

Zheng, Lianfang ^{[2
,4
]}

Zhang, Taiping ^{[1
,2
,5
]}

Zhao, Yupei ^{[1
,2
]}

机构：

[1] Chinese Acad Med Sci, Peking Union Med Coll Hosp, Dept Gen Surg, Beijing 100730, Peoples R China

[2] Peking Union Med Coll, Beijing 100730, Peoples R China

[3] Huazhong Univ Sci & Technol, Tongji Med Coll, Affiliated Tongji Hosp, Dept Biliary Pancreat Surg, Wuhan 430030, Hubei, Peoples R China

[4] Chinese Acad Med Sci, Peking Union Med Coll Hosp, Dept Nucl Med, Beijing 100730, Peoples R China

[5] Chinese Acad Med Sci, Clin Immunol Ctr, Beijing 100730, Peoples R China

来源：

CANCER LETTERS | 2017年 / 407卷

基金：

中国国家自然科学基金;

关键词：

PD-1/PD-L1; Immunotherapy; Pancreatic cancer; Immune resistance; Tumour microenvironment; REGULATORY T-CELLS; CHECKPOINT BLOCKADE; TUMOR MICROENVIRONMENT; ADOPTIVE IMMUNOTHERAPY; CLINICAL-SIGNIFICANCE; ANTI-PD-L1; ANTIBODY; SUPPRESSOR-CELLS; STEM-CELLS; THERAPY; GEMCITABINE;

D O I：

10.1016/j.canlet.2017.08.006

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

Therapy that targets programmed death 1 or programmed death 1 ligand 1 (PD-1/PD-L1), which are known as immune checkpoints, has been recently rapidly developing as oncotherapy for various carcinomas. However, this therapy has a poor effect on the treatment of pancreatic cancer with PD-1/PD-L1 blockade monotherapy. In this review, the development and limitations of anti-PD-1/PD-L1 mono therapy in pancreatic cancer are discussed. We then consider the underlying mechanism of anti-PD-1/PD-Ll monotherapy failure, combination strategies overcoming resistance to anti-PD-1/PD-L1 immunotherapy and the prospect of targeting PD-1/PD-L1 for the immunotherapy of pancreatic cancer. (C) 2017 Elsevier B.V. All rights reserved.

引用

页码：57 / 65

页数：9

共 89 条

[1]

Effectiveness and safety of poly (ADP-ribose) polymerase inhibitors in cancer therapy: A systematic review and meta-analysis [J].